DNA Cleavage Mediated by Bacterial Type II Topoisomerases.

Chelsea A Mann, Neil Osheroff

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chelsea A MannDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.

Neil OsheroffDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA. neil.osheroff@vanderbilt.edu.

Funding

Mechanistic Studies of Gyrase/Topoisomerase IV-Targeted AntibacterialsR01AI170546 · NIAID · VANDERBILT UNIVERSITY · PI NEIL OSHEROFF · 2023 to 2026

$2.7M

Mechanistic Studies of Type II Topoisomerases and Topoisomerase-Targeted AgentsR01GM126363 · NIGMS · VANDERBILT UNIVERSITY · PI OSHEROFF, NEIL · 2018 to 2025

$2.6M

NIAID NIH HHS R01 AI170546NIGMS NIH HHS R01 GM126363

6 · The paper itself

Abstract

The maintenance of DNA topology is critical for cellular processes. Topoisomerases are a class of enzymes found in eukaryotic and prokaryotic organisms that modulate the topology of DNA during replication and transcription. Bacterial type II topoisomerases, DNA gyrase and topoisomerase IV, are essential for bacterial cell survival. These enzymes pass an intact double helix through a transient double-stranded break in a separate segment of DNA in order to carry out their specific functions. The DNA cleavage step is crucial for the activity of the type II enzymes. However, prolongation of this process, for example, with exposure to antibacterial agents, can lead to bacterial cell death. The DNA cleavage assay is an in vitro method used to study the effects of type II topoisomerase-targeting compounds on enzyme-mediated DNA cleavage. This chapter outlines a protocol for measuring DNA cleavage mediated by Escherichia coli gyrase in the presence or absence of antibacterial drugs.

Indexed as

DNA, BacterialDNA CleavageDNA GyraseDNA Topoisomerases, Type IIEscherichia coliAnti-Bacterial AgentsDNA Topoisomerase IVTopoisomerase II InhibitorsAnti-Bacterial AgentsDNA, BacterialDNA GyraseDNA Topoisomerase IVDNA Topoisomerases, Type IITopoisomerase II InhibitorsAntibacterial drugsBacterial type II topoisomerasesDNA cleavageDNA gyrasePlasmid DNATopoisomerase IV

Identifiers

PMID40372637

DOI10.1007/978-1-0716-4550-5_6

PMCPMC12183650

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.